The utility of SPON1 alone or together with CA-125 [20–27] and/or Human epididymis protein 4 (HE4) [22, 28] should be determined in future experiments using serum samples from patients with ovarian cancer, other benign and malignant tumors, as well as samples from healthy individuals. This evidence concerns the gene SPON1 and ovarian cancer.